Certara, Inc. $CERT Shares Sold by Sei Investments Co.

Sei Investments Co. cut its holdings in Certara, Inc. (NASDAQ:CERT) by 43.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 620,967 shares of the company’s stock after selling 479,880 shares during the quarter. Sei Investments Co. owned about 0.40% of Certara worth $3,540,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Wasatch Advisors LP grew its stake in shares of Certara by 28.6% in the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after purchasing an additional 3,865,455 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Certara by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after purchasing an additional 175,024 shares in the last quarter. Deerfield Management Company L.P. lifted its stake in Certara by 71.7% during the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after purchasing an additional 2,813,438 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares during the last quarter. Finally, State Street Corp boosted its holdings in Certara by 2.2% during the fourth quarter. State Street Corp now owns 3,918,784 shares of the company’s stock worth $34,524,000 after buying an additional 83,698 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Performance

Shares of CERT opened at $8.13 on Friday. Certara, Inc. has a one year low of $4.45 and a one year high of $13.88. The company has a 50-day moving average of $6.52 and a two-hundred day moving average of $6.54. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -18.07 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 1.88.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm’s revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.07 EPS. On average, equities research analysts expect that Certara, Inc. will post 0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

CERT has been the topic of several recent research reports. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday. KeyCorp cut their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Craig Hallum reduced their price objective on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. BMO Capital Markets reduced their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Finally, Barclays lifted their target price on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Certara has a consensus rating of “Hold” and a consensus target price of $8.28.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.